-
FAM83H-AS1: New Noninvasive Ovarian Cancer Biomarker
04 Feb 2026 01:44 GMT
… earlier detection of ovarian cancer, which drastically improves treatment options and patient … cancer but also in developing innovative treatment modalities.
In the quest … we detect, diagnose, and ultimately treat ovarian cancer.
In conclusion, the emergence …
-
Clearwater woman battles extraordinarily rare ovarian cancer linked to brain tumor tissue
03 Feb 2026 19:47 GMT
Ainsley Cole, a Dunedin High School graduate and University of South Florida psychology student, is battling an exceptionally rare form of cancer doctors say they may only encounter once in a career. FOX 13's Jennifer Kveglis reports.
CLEARWATER, Fla. …
-
<![CDATA[Women Leading Biotech: Advancing Treatments for Ovarian Cancer]]>
03 Feb 2026 18:17 GMT
… for advanced ovarian cancer in phase 3 development. The company … advanced ovarian cancer. I have worked in the pharmaceutical and … journey to transform the ovarian cancer treatment landscape for women … hear clinicians and our trial investigators speak about …
-
The Relationship Between Symptom Burden and Death Anxiety in Ovarian Cancer Patients: The Mediating Effect of Alexithymia
03 Feb 2026 15:27 GMT
… and chemotherapy are important treatment modalities for ovarian cancer patients, leading to various … anxiety and fear. Consequently, we develop psychological defense mechanisms to cope …
-
Long Shortz with Imagion Biosciences: Key FDA milestone reached for MagSense
03 Feb 2026 22:46 GMT
… an Investigational New Drug application with the US FDA.
The conversation also … and ovarian cancer.
Tune in to hear more.
This video was developed in …
-
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference
03 Feb 2026 21:05 GMT
… Zentalis Pharmaceuticals
Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer … our confirmatory APSENOVA Phase 3 trial; and our planned regulatory strategy …
-
Better care for ovarian cancer is possible, and long overdue
03 Feb 2026 09:27 GMT
… of our health system: ovarian cancer.
Findings from the Bangladesh … symptoms of ovarian cancer to life during and after treatment.
The … how the disease typically develops. Knowledge of genetic risk … in Bangladesh continues to treat it as one. Without …
-
<![CDATA[Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer]]>
03 Feb 2026 02:44 GMT
… a potential future direction for development:
OS: Not available … treatment (HR, 0.99; P = .488).
cTMB-high / intent-to-treat … drug approvals. Between 2006 and 2023, only 22% of FDA … #47;HRP ovarian cancer patients; phase 2b VITAL trial analysis published …
-
Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA
03 Feb 2026 13:45 GMT
… Drug Administration and its continued advancement toward a first-in-human trial … from the FDA on Ernexa’s development strategy for … treat autoimmune disease. The company’s initial focus is to develop … ERNA-101 for the treatment of ovarian cancer. For …
-
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
03 Feb 2026 13:00 GMT
… clinical-stage pharmaceutical company dedicated to developing stenoparib … from our ongoing trial in ovarian cancer, stenoparib has … drug. By screening patients before treatment, and only treating … development of stenoparib (2X-121) in advanced ovarian cancer …
About
© 1995-2026